List of upcoming coronavirus vaccines

Adopted from:
See also: Absolutely Maybe blog about vaccines and medicine for monthly news.
MT-001a novel protein component vaccine candidate, MT-001, based on a fragment of the SARS-CoV-2 spike protein that encompasses the receptor binding domain (RBD) | A SARS-CoV-2 Vaccine Designed for Manufacturability Results in Unexpected Potency and Non-Waning Humoral Response - Mice and hamsters immunized with a prime-boost regimen of MT-001 demonstrated extremely high anti-spike IgG titers, and remarkably this humoral response did not appreciably wane for up to 12 months following vaccination. Further, virus neutralization titers, including titers against variants such as Delta and Omicron BA.1, remained high without the requirement for subsequent boosting.
DCFHPa ferritin-based, protein-nanoparticle vaccine candidate that, when formulated with aluminum hydroxide as the sole adjuvant (DCFHP-alum), elicits potent and durable neutralizing antisera in non-human primates against known VOCs, including Omicron BQ.1, as well as against SARS-CoV-1. | A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates.
UPDATE 2023-07-31:
ISM3312a COVID-19 drug entirely designed by generative AI works by inhibiting a protein called 3CL protease -- a critical factor in viral replication and a popular target for anti-COVID drugs. Unlike similar therapeutics, it works on a very broad spectrum -- showing efficacy not only against all current COVID variants, but also coronaviruses other than SARS-CoV-2. As such, it may possess the ability to resist future mutations, providing a solution to drug-resistant strains. World's first generative AI-designed COVID drug to start clinical trials
BNT162b4composed of a T cell antigen mRNA encoding for SARS-CoV-2 non-spike proteins that are highly conserved across a broad range of SARS-CoV-2 variants and will be evaluated in combination with the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine | Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection
25F9 and 20A7identified as two highly potent broadly neutralizing antibodies, making them promising prophylactic candidates against sarbecovirus infection |Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine -- Science Translational Medicine --
ChAd-SARS-CoV-2-BA.5-Sencodes for a pre- fusion and surface-stabilized S protein of the BA.5 strain. | A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamsters